Posts in tag


Published Studies Provide Further Support For Kalytera’s Program Evaluating CBD in GVHD

SAN FRANCISCO and TEL AVIV, Israel, Nov. 22, 2019 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) today announced that research reported in two peer-reviewed articles published in Blood provide further evidence supporting the activity of cannabidiol (“CBD”) in prevention and treatment of acute graft versus host …